On July 5th, it was learned from Harbin Institute of Technology that the university's research team has made significant progress in the field of precision treatment for glioblastoma. The "Trojan Nanorobot" developed by the research team successfully crossed the blood-brain barrier in tumor model mice, actively targeting and delivering drugs to the central area of tumor lesions in glioma model mice, bringing a new solution for the treatment of malignant brain tumors. The relevant research results were published in the international journal Nature Communications. Glioma is currently the most invasive and lethal malignant brain tumor, and clinical treatment faces enormous challenges. The blood-brain barrier blocks most drugs from entering the brain, and the complex microenvironment inside tumor tissue makes it difficult for drugs to penetrate deep into the tumor, affecting the clinical efficacy of chemotherapy. Faced with this medical challenge, the team innovatively proposed the concept of "Trojan nanorobots", which cleverly hide enzyme driven nanorobots loaded with drugs inside neutrophil robots through bacterial membrane camouflage technology. If nanorobots are directly injected into the bloodstream, they will be cleared by immune cells. Now, hiding them inside the neutrophil robot avoids the body's immune surveillance and will not be cleared by immune cells, "explained He Qiang, a professor at the Department of Life Sciences and Medicine at Harbin Institute of Technology. By leveraging the natural sensitivity of neutrophils to tumor chemical signals, neutrophil robots equipped with enzyme driven nanorobots can autonomously sense the gradient of chemical signaling factors released by gliomas, actively cross the blood-brain barrier, and quickly release enzyme driven nanorobots. These nanorobots can autonomously sense the concentration of hydrogen peroxide produced by the metabolism of gliomas, break through multiple physiological barriers in the tumor microenvironment, and actively penetrate into the center of the tumor lesion to release drugs, significantly improving the tissue permeability and targeting of drugs. The results of in vivo experiments on mice showed that the enzyme driven nanorobot's active targeting efficiency reached 5 times that of conventional nanoparticles, effectively inhibiting tumor growth. At the same time, the system has good safety and biocompatibility, demonstrating excellent therapeutic potential. This research achievement is not only expected to change the treatment strategy of glioma, but also bring hope for precise treatment of other brain diseases. (New Society)